Abstracts Archive - Page 181 of 2607 - ACR Meeting Abstracts

Abstract Number: 1356 • ACR Convergence 2025
Use of (MSB11456), the first tocilizumab biosimilar approved for rheumatoid arthritis: 6-month data from an international observational study
Jonathan Kay¹, Eugen feist², Ernest Choy³, Joerg Kaufmann⁴, Ernest Wong⁵, Hector Corominas⁶, René-Marc Flipo⁷, Jérôme Avouac⁸, María América López Lasanta⁹, Joelle Monnet¹⁰, Peter Baker¹¹, Maria Romanova Michailidi¹², Fabrizio Dolfi¹¹ and Graziella Pourcel¹³, ¹UMass Chan Medical School, Worcester, MA, ²Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ³Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, ⁴NA, Ludwigsfelde, Germany, ⁵Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom, ⁶Hospital de Sant Pau, Barcelona, Spain, ⁷Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, Lille, France, ⁸Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁹Hospital Universitario Vall d´Hebron, Barcelona, Spain, ¹⁰Fresenius Kabi SwissBioSim, Eysins, Switzerland, ¹¹Fresenius Kabi Biopharma, Eysins, Switzerland, ¹²University of Geneva, Eysins, Switzerland, ¹³Fresenius Kabi Biopharma, Eyzins, France
Background/Purpose: Although most healthcare professionals are convinced of the quality, safety, and favorable economic impact of biosimilars, their routine use is not yet widespread. MSB11456…
Abstract Number: 1373 • ACR Convergence 2025
Effect of JAK Inhibitors on Bone Mineral Density in Rheumatoid Arthritis Patients with Osteoporosis: A Comparative Study with Biologics
Sungwon Ko¹, Young-Eun Kim¹, Soo Min Ahn¹, Ji Seon Oh¹, Yong-Gil Kim¹, Chang-Keun Lee², Bin Yoo¹ and Seokchan Hong¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, Seoul, Republic of Korea, ²Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Seoul, Republic of Korea
Background/Purpose: Osteoporosis is more prevalent in patients with rheumatoid arthritis (RA) than in the general population. Janus kinase (JAK) inhibitors and tumor necrosis factor (TNF)…
Abstract Number: 1385 • ACR Convergence 2025
Characterizing Isolated Dryness Phenotypes in Sjögren’s Syndrome
Giovanni Fulvio¹, Rossana Izzetti², Francesco Gulia², Valentina Donati³, Gaetano La Rocca⁴, Inmaculada Concepción Navarro García⁵, Beatrice Dei¹, Francesco Ferro⁶, Marta Mosca⁷ and Chiara Baldini⁷, ¹Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, ²University of Pisa, Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, Unit of Dentistry and Oral Surgery, Pisa, Italy, ³Azienda Ospedaliero-Universitaria Pisana (AOUP), Unit of Pathological Anatomy ², Pisa, Italy, ⁴University of Pisa, Rheumatology Unit, Pisa, Pisa, Italy, ⁵University of Pisa, Clinical and Experimental Medicine, Rheumatology Unit, Pisa, Italy, ⁶Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ⁷University of Pisa, Pisa, Pisa, Italy
Background/Purpose: Ocular and oral dryness, occurring in isolation, represent distinct phenotypic subsets within Sjögren’s disease (SjD). However, potential differences in glandular imaging findings and pathophysiological…
Abstract Number: 1293 • ACR Convergence 2025
Synovitis and periarticular soft tissues abnormalities in childhood-onset systemic lupus erythematosus: an ultrasonography study
Marianna Freire¹, Jean Paulo Veronese de Souza¹, Ana Renata Oliveira¹, Renata Kobayasi², Vitor Paula³, Clovis Artur Silva⁴ and Lucia Maria Campos⁵, ¹Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clínicas HCFMUSP, São Paulo, Sao Paulo, Sao Paulo, Brazil, ²Centro de Desenvolvimento de Educação Médica do Hospital das Clínicas HCFMUSP, São Paulo, Sao Paulo, Sao Paulo, Brazil, ³Pediatric Radiology Unit, Instituto da Criança e do Adolescente, Hospital das Clínicas HCFMUSP, São Paulo, Sao Paulo, Sao Paulo, Brazil, ⁴University of São Paulo, São Paulo, São Paulo, Brazil, ⁵Instituto da Criança e do Adolescente, São Paulo, São Paulo, Brazil
Background/Purpose: Musculoskeletal (MSK) involvement occurs in up to 70% of childhood-onset systemic lupus erythematosus (cSLE). MSK ultrasound (US) has emerged as a tool with greater…
Abstract Number: 1374 • ACR Convergence 2025
AZD1163, a Novel Bispecific Human Antibody Targeting PAD2/4 Enzymes Responsible for Generating Citrullinated Protein Auto-antigens in Rheumatoid Arthritis, Demonstrates Dose-dependent Inhibition of Systemic PAD Activity in Healthy Volunteers
Susanne Prothon¹, Jacob Leander¹, Ulla Seppälä¹, Eduard Molins², Mia Collins¹, Nicholas White³, Ivonne Puente¹, Andre Santa Maria¹, Gary Sims⁴, David Han⁵, Obada Al Hamdan⁶, Ronald Goldwater⁷, Emon Khan⁸ and David Close⁹, ¹AstraZeneca, Gothenburg, Sweden, ²AstraZeneca, Barcelona, Spain, ³AstraZeneca, Cambridge, United Kingdom, ⁴AstraZeneca, Gaithersburg, ⁵Parexel, Los Angeles, ⁶Parexel, Berlin, Germany, ⁷Parexel, Baltimore, ⁸BioPharmaceuticals R&D, Late Respiratory and Immunology, AstraZeneca, Academy House, Cambridge, United Kingdom, ⁹AstraZeneca, Royston, United Kingdom
Background/Purpose: AZD1163 is a novel bispecific antibody that inhibits the activity of extracellular Peptidyl Arginine Deiminases (PADs) 2 and 4, enzymes responsible for protein citrullination…
Abstract Number: 1333 • ACR Convergence 2025
Assessment of lipid abnormalities after initiation of a JAK inhibitor in rheumatoid arthritis in clinical practice
Salomé Abdellaoui¹, Omar Al Tabaa¹, Sophie Hecquet¹, Alice Combier¹, Sandrine Carves¹, Olivier Fogel², Yannick Allanore³ and Jérôme Avouac⁴, ¹Rheumatology department, Cochin Hospital, Paris, France, ²AP-HP, Paris, France, ³Université Paris Cité, Paris, France, ⁴Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: rheumatoid arthritis (RA) is characterized by a lipid paradox induced by systemic inflammation. JAK inhibitors (JAKi) have been associated with a short-term increase in…
Abstract Number: 1394 • ACR Convergence 2025
Burden of Comorbidities Across EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) Domains: Treatment Prevalence Among Commercially Insured Sjögren’s Patients in the United States
Minoti Ganguli, Annie Kilby, Ahva Shahabi and Tsu-Chieh Jay Lin, Amgen Inc., Thousand Oaks, CA
Background/Purpose: Sjögren’s disease (SjD) is a systemic disorder characterized by exocrine gland inflammation, leading to dry eyes/mouth, and multiple organ systems involvement1. The European League…
Abstract Number: 1391 • ACR Convergence 2025
Assessment of Anti-SSA/Ro Testing Across Various Commercial Laboratories in the United States to Reduce the Burden of Surveillance in Pregnant Women with No History of Fetal Atrioventricular Block (fAVB)
Mala Masson¹, Bettina Cuneo², Philip Carlucci³, Peter Izmirly⁴, Justin Brandt⁵, Colin Phoon⁶, Ashley Roman⁶, Amit Saxena⁷, Michael Belmont⁵, Christina Penfield⁶, Young Mi Lee⁶, Julie Nusbaum⁵, Andrew Rubenstein⁶, Elena Sinkovskaya⁸, Alfred Abuhamad⁸, Gary Satou⁹, Whitnee Hogan¹⁰, Anita Moon-Grady¹¹, Lisa Howley¹², Mary Donofrio¹³, Stephanie Levasseur¹⁴, Miwa Geiger¹⁵, Sonal Owens¹⁶, Kristopher Cumbermack¹⁷, Jyothi Matta¹⁸, Gary Joffe¹⁹, Christopher Lindblade²⁰, Caitlin Haxel²¹, Katherine Kohari²², Joshua Copel²², James Strainic²³, Tam Doan²⁴, Conisha Holloman²⁴, Stacy Killen²⁵, Theresa Tacy²⁶, Michelle Kaplinski²⁶, Nalani Sachan⁶, Nicola Fraser⁶, Robert Clancy¹⁴ and Jill Buyon⁶, ¹NYU Langone Medical Center- Division of Rheumatology, New York, NY, ²University of Arizona College of Medicine, Tucson, AZ, ³New York University School of Medicine, New York, NY, ⁴New York University Grossman School of Medicine, New York, NY, ⁵NYU Langone Health, New York, NY, ⁶NYU Grossman School of Medicine, New York, NY, ⁷Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁸Eastern Virginia Medical School, Norfolk, VA, ⁹University of California Los Angeles, Los Angeles, CA, ¹⁰University of Utah, Salt Lake City, UT, ¹¹University of California San Francisco, San Francisco, CA, ¹²Midwest Fetal Care Center, Children's Minnesota/Allina Health, Minneapolis, MN, ¹³Children's National Hospital, Washington, DC, ¹⁴Columbia University, New York, NY, ¹⁵Mount Sinai School of Medicine, New York, NY, ¹⁶University of Michigan, Ann Arbo, MI, ¹⁷University of Kentucky, Lexington, KY, ¹⁸University of Louisville, Louisville, KY, ¹⁹Perinatal Associates of New Mexico, Albuquerque, NM, ²⁰Phoenix Children's Hospital, Phoenix, AZ, ²¹University of Vermont Children's Hospital, Burlington, VT, ²²Yale University, New Haven, CT, ²³UH Rainbow Babies, Cleveland, OH, ²⁴Baylor College of Medicine, Houston, TX, ²⁵Vanderbilt University, Nashville, TN, ²⁶Stanford University, Stanford, CA
Background/Purpose: For women with Sjögren's disease, the risk of Fetal Atrioventricular Block (fAVB) is a critical aspect in pregnancy counseling. To date, the most reliable…
Abstract Number: 1378 • ACR Convergence 2025
Prevalence of Central Nervous System Manifestations in Sjögren’s Disease
Arun Varadhachary¹, Ghaith Noaiseh², Katherine Hammitt³, Julie Frantsve-Hawley³, Paula Barreras Cortes⁴, Shamik Bhattacharyya⁵, E. Sherwood Brown⁶, Drew Carey⁷, Robert Fox⁸, Brent Goodman⁹, Thomas Grader-Beck¹⁰, Janet Lewis¹¹, Stephen Maitz¹², Steven Mandel¹³, Jenifer McCombe¹⁴, Astrid Rasmussen¹⁵, George Sarka¹⁶, Daniel Wallace¹⁷, Frederick Vivino¹⁸, Rochelle Zak¹⁹, Nancy Carteron²⁰, R Hal Scofield¹⁵ and Steven Carsons²¹, ¹Washington University in St. Louis, St. Louis, MO, ²University of Kansas Medical Center, Kansas City, KS, ³Sjogren's Foundation, Reston, VA, ⁴Cedars Sinai, Los Angeles, CA, ⁵Brigham and Women's Hospital, Malden, MA, ⁶UT Southwestern Medical Center, Dallas, TX, ⁷Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Rheumatology Clinic, San Diego, CA, ⁹HonorHealth, Scottsdale, AZ, ¹⁰Johns Hopkins, Reisterstown, MD, ¹¹University of Virginia, Charlottesville, VA, ¹²U.S. Department of Veterans Affairs, Coatesville, PA, ¹³Donald and Barbara Zucker School of Medicine and Hofstra/Northwell, Hempstead, NY, ¹⁴University of Alberta, Edmonton, AB, Canada, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Cedars-Sinai Medical Center, Laguna Hills, CA, ¹⁷Cedars Sinai Medical Center, Studio City, CA, ¹⁸University of Pennsylvania, Bryn Mawr, PA, ¹⁹UCSF Health, San Francisco, CA, ²⁰University of California, Berkeley & San Francisco, Angwin, CA, ²¹NYU Long Island School of Medicine, Mineola, NY
Background/Purpose: Sjögren’s disease is a systemic autoimmune disorder with diverse clinical manifestations affecting multiple organ systems. While dry mouth, dry eyes, fatigue and pain are…
Abstract Number: 1395 • ACR Convergence 2025
A Comparative Study of Yao Syndrome and Primary Sjögren’s Syndrome
Nayaab Bakshi¹, Christopher Loh², Song Wu³ and Qingping Yao³, ¹Stony Brook University, Dix Hills, NY, ²Stony Brook University, Lake Grove, NY, ³Stony Brook University, Stony Brook, NY
Background/Purpose: Yao syndrome (YAOS, OMIM 617321) is formerly named Nucleotide-binding oligomerization domain containing protein 2 (NOD2)-associated autoinflammatory disease affecting multiorgan systems characterized by recurrent fever,…
Abstract Number: 1343 • ACR Convergence 2025
Six-Minute Walk Distance as a Functional Measure in Rheumatoid Arthritis-associated Interstitial Lung Disease Reflecting Both Lung and Joint Involvement
Sung Hae Chang¹, You-Jung Ha², Sung Won Lee³, Misti Paudel⁴, Gregory McDermott⁵, Qianru Zhang⁶, Min Uk Kim⁷, Jeong Seok Lee⁸, Chan Ho Park⁹, Ji-Won Kim¹⁰, Jang Woo Ha¹¹, SANGWAN CHUNG¹², Eun Ha Kang¹³, Yeon-Ah Lee¹², Yong-Beom Park¹⁴, Jung-Yoon Choe¹⁵, Eun Young Lee¹⁶ and Jeffrey Sparks¹⁷, ¹Soonchunhyang University College of Medicine, Cheonan, MA, South Korea, ²Seoul National University Bundang Hospital, Seongnam, South Korea, ³Soon Chun Hyang University Hospital, Seoul, South Korea, ⁴Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶Harvard Medical School, Boston, MA, ⁷SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, ⁸Korea Advanced Institute of Science and Technology, KAIST, DaeJeon, Republic of Korea, ⁹Soonchunhyang University College of Medicine, Cheonan, Republic of Korea, ¹⁰Daegu Catholic University School of Medicine, Nam-gu, Daegu, Republic of Korea, ¹¹Division of Rheumatology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Republic of Korea, ¹²Kyung Hee University Medical Center, seoul, Republic of Korea, ¹³Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ¹⁴Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, ¹⁵Division of Rheumatology, Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Republic of Korea, ¹⁶Seoul National University College of Medicine, Seoul, South Korea, ¹⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: The six-minute walk distance (6MWD) measures functional capacity in cardiopulmonary diseases, predicts mortality in interstitial lung disease (ILD), and is used as an endpoint…
Abstract Number: 1380 • ACR Convergence 2025
Phenotyping Neuropathic Pain in Sjögren’s Disease: A Cluster-Based Approach
Beatrice Dei¹, Stefano Donati¹, Gaetano La Rocca², Giovanni Fulvio¹, Federico Fattorini¹, Antonello Sulis¹, Michele Moretti¹, Elena Elefante¹, Francesco Ferro³, Giulia Ricci⁴, Marta Mosca⁵ and Chiara Baldini⁵, ¹Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, ²University of Pisa, Rheumatology Unit, Pisa, Pisa, Italy, ³Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ⁴Neurology Unit, University of Pisa, Pisa, Toscana, Italy, ⁵University of Pisa, Pisa, Pisa, Italy
Background/Purpose: Neuropathic pain (NeP) is increasingly recognized as a relevant symptom domain in primary Sjögren’s disease (SjD), contributing to the disease burden beyond glandular involvement.…
Abstract Number: 1404 • ACR Convergence 2025
Higher cardiovascular risk and lymphoma development in primary Sjögren’s Syndrome with extraglandular involvement
Teresa Blázquez Sánchez¹, Antía García Fernández¹, Jorge Mairal Monesma², Arantxa Torres Roselló³, Elena Heras Recuero⁴, Raquel Largo Carazo⁵, Juan Antonio Martínez López⁶ and Miguel A. González-Gay⁷, ¹Fundacion Jiménez Díaz, Madrid, Madrid, Spain, ²Instituto de Investigacion Fundación Jiménez Díaz, Madrid, Spain, ³Fundacion Jiménez Díaz, Madrid, Spain, ⁴Hospital Fundacion Jimenez Dias, Madrid, Spain, ⁵Instituto de Investigacion Fundacion Jiménez Díaz, Madrid, Spain, ⁶Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain, ⁷Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain
Background/Purpose: Primary Sjögren’s syndrome (pSS) can have a systemic involvement with extraglandular manifestations, which are associated with more severe disease and with higher risk of…
Abstract Number: 1393 • ACR Convergence 2025
Prevalence of Sjögren’s Disease in the United States – A Retrospective Cohort Study Among a Commercially Insured Population (2019-2023)
Minoti Ganguli, Annie Kilby, Ahva Shahabi and Tsu-Chieh Jay Lin, Amgen Inc., Thousand Oaks, CA
Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune condition characterized by diverse clinical manifestations, which often complicates diagnosis and disease management1. Previous epidemiological estimates of…
Abstract Number: 1402 • ACR Convergence 2025
Understanding Fatigue Through Patients’ Eyes: Development of a Novel Questionnaire Capturing the Complexity of Real-Life Fatigue in Sjögren’s Disease
Saviana Gandolfo¹, Flavia Riccio², Mariachiara Visconti³, Corrado Parlati³, Nicola Della Rossa⁴, Enrico Tirri⁵ and Francesco Ciccia³, ¹Rheumatology Unit, Ospedale del mare, Naples, Naples, Naples, Italy, ²Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Napoli, Italy, ³Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, Italy, ⁴Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, ⁵Rheumatology Unit, Ospedale del mare, Naples, Italy, Naples, Italy
Background/Purpose: Fatigue is one of the most frequent, debilitating and impactful symptoms for patients with Sjögren's Disease (SjD), and one of the most challenging to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].